drugset / Trial / NCT00497081
Mirtazapine to Reduce Methamphetamine Use Among MSM With High-risk HIV Behaviors
Phase 2
Completed
60 enrolled
San Francisco Department of Public Health
National Institute on Drug Abuse (NIDA) · collabPublic Health Foundation Enterprises, Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Studies demonstrate that methamphetamine (meth) use is associated with high-risk sexual behavior among MSM, putting meth-using MSM at extraordinarily high risk for transmitting or acquiring HIV. This study of intermediate size (60 participants) and length (3 months of follow-up) will assess the efficacy of mirtazapine in reducing methamphetamine use among high-risk MSM.
Timeline
- Start
- 2007-05
- Primary completion
- 2010-03
- Completion
- 2010-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Mirtazapine | Other / unclassified | 30 mg | Oral |